Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility.

Recent advances in proteomic profiling technologies, such as surface enhanced laser desorption ionization mass spectrometry, have allowed preliminary profiling and identification of tumor markers in biological fluids in several cancer types and establishment of clinically useful diagnostic computational models. There are currently no routinely used circulating tumor markers for renal cancer, which is often detected incidentally and is frequently advanced at the time of presentation with over half of patients having local or distant tumor spread. We have investigated the clinical utility of surface enhanced laser desorption ionization profiling of urine samples in conjunction with neural-network analysis to either detect renal cancer or to identify proteins of potential use as markers, using samples from a total of 218 individuals, and examined critical technical factors affecting the potential utility of this approach. Samples from patients before undergoing nephrectomy for clear cell renal cell carcinoma (RCC; n = 48), normal volunteers (n = 38), and outpatients attending with benign diseases of the urogenital tract (n = 20) were used to successfully train neural-network models based on either presence/absence of peaks or peak intensity values, resulting in sensitivity and specificity values of 98.3-100%. Using an initial "blind" group of samples from 12 patients with RCC, 11 healthy controls, and 9 patients with benign diseases to test the models, sensitivities and specificities of 81.8-83.3% were achieved. The robustness of the approach was subsequently evaluated with a group of 80 samples analyzed "blind" 10 months later, (36 patients with RCC, 31 healthy volunteers, and 13 patients with benign urological conditions). However, sensitivities and specificities declined markedly, ranging from 41.0% to 76.6%. Possible contributing factors including sample stability, changing laser performance, and chip variability were examined, which may be important for the long-term robustness of such approaches, and this study highlights the need for rigorous evaluation of such factors in future studies.

[1]  M. Resnick,et al.  Two-dimensional analysis of proteins in unprocessed human urine using double stain. , 1993, The Journal of urology.

[2]  O. Vesterberg,et al.  Unconcentrated human urinary proteins analysed by high resolution two‐dimensional electrophoresis with narrow pH gradients: Preliminary findings after occupational exposure to cadmium , 1985 .

[3]  J. J. Edwards,et al.  Proteins of human urine. II. Identification by two-dimensional electrophoresis of a new candidate marker for prostatic cancer. , 1982, Clinical chemistry.

[4]  M. Schrader,et al.  Human beta-defensin-1: A urinary peptide present in variant molecular forms and its putative functional implication. , 1998, European journal of medical research.

[5]  O John Semmes,et al.  Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  A. Belldegrun,et al.  The changing natural history of renal cell carcinoma. , 2001, The Journal of urology.

[7]  M S Pepe,et al.  Phases of biomarker development for early detection of cancer. , 2001, Journal of the National Cancer Institute.

[8]  G. Wright,et al.  Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. , 2001, The American journal of pathology.

[9]  Geoffrey E. Hinton,et al.  Learning internal representations by error propagation , 1986 .

[10]  J. Glaspy Therapeutic options in the management of renal cell carcinoma. , 2002, Seminars in oncology.

[11]  Michael B Cohen,et al.  Biomarkers for the Detection of Bladder Cancer , 2001, Advances in anatomic pathology.

[12]  M. Hammond,et al.  Issues and barriers to development of clinically useful tumor markers: a development pathway proposal. , 2002, Seminars in oncology.

[13]  E. Petricoin,et al.  Serum proteomic patterns for detection of prostate cancer. , 2002, Journal of the National Cancer Institute.

[14]  S. Huang,et al.  Urinary NMP22 and renal cell carcinoma. , 2000, Urology.

[15]  D. Dunger,et al.  Freezing method affects the concentration and variability of urine proteins and the interpretation of data on microalbuminuria , 2000, Diabetic medicine : a journal of the British Diabetic Association.

[16]  M. Dowsett,et al.  Biological markers: maintaining standards , 2000, British Journal of Cancer.

[17]  P. Schellhammer,et al.  Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. , 2002, Cancer research.

[18]  B. Konety,et al.  Urine based markers of urological malignancy. , 2002, The Journal of urology.

[19]  D. Chan,et al.  Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. , 2002, Clinical chemistry.

[20]  Uwe Claussen,et al.  Mass spectrometry meets chip technology: A new proteomic tool in cancer research? , 2001, Electrophoresis.

[21]  D. Vonderschmitt,et al.  Electrophoretic, chromatographic and immunological studies of human urinary proteins , 1995, Electrophoresis.

[22]  J. J. Edwards,et al.  Proteins of human urine. III. Identification and two-dimensional electrophoretic map positions of some major urinary proteins. , 1982, Clinical chemistry.

[23]  N. Anderson,et al.  Proteins of human urine. I. Concentration and analysis by two-dimensional electrophoresis. , 1979, Clinical chemistry.

[24]  R. Wahl,et al.  Towards defining the urinary proteome using liquid chromatography‐tandem mass spectrometry I.Profiling an unfractionated tryptic digest , 2001, Proteomics.

[25]  D. L. Diamond,et al.  Detection of β-defensins secreted by human oral epithelial cells , 2001 .

[26]  M. Goligorsky,et al.  Toward proteomics in uroscopy: urinary protein profiles after radiocontrast medium administration. , 2001, Journal of the American Society of Nephrology : JASN.

[27]  R. Bast,et al.  Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. , 1996, Journal of the National Cancer Institute.

[28]  B. Koçak,et al.  Value of urinary NMP-22 in patients with renal cell carcinoma. , 2002, Urology.

[29]  E. Petricoin,et al.  Rapid protein display profiling of cancer progression directly from human tissue using a protein biochip , 2000 .

[30]  G. Wright,et al.  Proteinchip® surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures , 1999, Prostate Cancer and Prostatic Diseases.

[31]  S. Weinberger,et al.  Recent advancements in surface‐enhanced laser desorption/ionization‐time of flight‐mass spectrometry , 2000, Electrophoresis.

[32]  D. Sargent,et al.  Issues in clinical trial design for tumor marker studies. , 2002, Seminars in oncology.

[33]  S M Hanash,et al.  Proteomic Approaches within the NCI Early Detection Research Network for the Discovery and Identification of Cancer Biomarkers , 2001, Annals of the New York Academy of Sciences.

[34]  Peter Albers,et al.  Analysis of microdissected prostate tissue with ProteinChip arrays--a way to new insights into carcinogenesis and to diagnostic tools. , 2002, International journal of molecular medicine.

[35]  Christina H. Park,et al.  Human beta-defensin-1: an antimicrobial peptide of urogenital tissues. , 1998, The Journal of clinical investigation.

[36]  W. Sadler,et al.  The Effect of Storage Ph on the Precipitation of Proteins in Deep Frozen Urine Samples , 1987, Annals of clinical biochemistry.

[37]  P. Schellhammer,et al.  Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. , 2002, Clinical chemistry.

[38]  M. Nakazato,et al.  Structural analysis of human beta-defensin-1 and its significance in urinary tract infection. , 2000, Nephron.

[39]  M. Rubin,et al.  Molecular markers for renal cell carcinoma: impact on diagnosis and treatment. , 2001, Seminars in urologic oncology.

[40]  B. Kramer,et al.  Trends in biomarker research for cancer detection. , 2001, The Lancet. Oncology.

[41]  J. X. Pang,et al.  Biomarker discovery in urine by proteomics. , 2002, Journal of proteome research.

[42]  F. Marshall,et al.  Beta Defensin-1, Parvalbumin, and Vimentin: A Panel of Diagnostic Immunohistochemical Markers for Renal Tumors Derived From Gene Expression Profiling Studies Using cDNA Microarrays , 2003, The American journal of surgical pathology.

[43]  Y. Lee,et al.  Urinary proteins with pro-apoptotic and antitumor activity , 2000, Apoptosis.

[44]  J. Celis,et al.  Towards a comprehensive database of proteins from the urine of patients with bladder cancer. , 1996, The Journal of urology.

[45]  K. Lillemoe,et al.  Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. , 2002, Cancer research.

[46]  P. Schellhammer,et al.  Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. , 2001, Cancer research.

[47]  J. Celis,et al.  Psoriasin (S100A7): A putative urinary marker for the follow‐up of patients with bladder squamous cell carcinomas , 1999, Electrophoresis.

[48]  M. Nakazato,et al.  Structural Analysis of Human β-Defensin-1 and Its Significance in Urinary Tract Infection , 2000, Nephron.

[49]  U. Stenman Tumor-associated trypsin inhibitor. , 2002, Clinical chemistry.

[50]  A. Rodríguez-Cuartero,et al.  Urinary beta-glucuronidase in renal cell carcinoma. , 2000, Clinical nephrology.

[51]  James L. McClelland,et al.  Parallel distributed processing: explorations in the microstructure of cognition, vol. 1: foundations , 1986 .